Attached files

file filename
EX-99.1 - ALBANY MOLECULAR RESEARCH INCv231233_ex99-1.htm
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 

 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 8, 2011
 
ALBANY MOLECULAR RESEARCH, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
 
000-25323
 
14-1742717
(State or other jurisdiction
 
(Commission
 
(IRS Employer
of incorporation)
 
File Number)
 
Identification No.)

21 Corporate Circle, P.O. Box 15098, Albany,
 
12212
NY
   
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (518) 512-2000
 
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
 

 
 
Item 2.02     Results of Operations and Financial Condition
 
On August 8, 2011, Albany Molecular Research, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2011.  That release referred to certain attached financial highlights for the three and six months ended June 30, 2011.  The full text of the press release, including the financial tables referred to within the release, which were posted on the Company’s internet website, are furnished as Exhibit 99.1 hereto and are incorporated by reference herein.
 
Item 9.01     Financial Statements and Exhibits
 
 
(d)
Exhibits

 
99.1
Press release and financial tables dated August 8, 2011, issued by Albany Molecular Research, Inc.
 
 
1

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 8, 2011
ALBANY MOLECULAR RESEARCH, INC.
     
 
By:
/s/ Mark T. Frost
   
Mark T. Frost
   
Senior Vice President, Administration,
Chief Financial Officer and Treasurer
 
 
2

 
 
EXHIBIT INDEX
 
Exhibit No.
  
Description
99.1
 
Press release dated August 8, 2011